Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma

Genetically engineered mouse (GEM) models of ovarian cancer that closely recapitulate their human tumor counterparts may be invaluable tools for preclinical testing of novel therapeutics. We studied murine ovarian endometrioid adenocarcinomas (OEA) arising from conditional dysregulation of canonical...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2011-12, Vol.17 (23), p.7359-7372
Hauptverfasser:	RONG WU, HU, Tom C, REHEMTULLA, Alnawaz, FEARON, Eric R, CHO, Kathleen R
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic agents Biological and medical sciences Carcinoma, Endometrioid - drug therapy Carcinoma, Endometrioid - metabolism Carcinoma, Endometrioid - pathology Cell Line, Tumor Cell Proliferation - drug effects Cisplatin - administration & dosage Cisplatin - therapeutic use Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Mice Ovarian Neoplasms - drug therapy Ovarian Neoplasms - metabolism Ovarian Neoplasms - pathology Paclitaxel - administration & dosage Paclitaxel - therapeutic use Pharmacology. Drug treatments Phosphatidylinositol 3-Kinases - antagonists & inhibitors Phosphatidylinositol 3-Kinases - metabolism Proto-Oncogene Proteins c-akt - antagonists & inhibitors Proto-Oncogene Proteins c-akt - metabolism Sirolimus - administration & dosage Sirolimus - therapeutic use TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - metabolism Tumors Wnt Signaling Pathway - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!